A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-06-29
Adverse events
Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-08-24 (study day 40); relationship: not assessed; serious criteria: hospitalization
Grade 2 Hyperthyroidism — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 68); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-20 (study day 370); relationship: not assessed
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2023-08-07 (study day 388); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 402); relationship: Y
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-26 (study day 620); relationship: N; serious criteria: hospitalization
Data queries
No data queries.